ArticleJournal of drug delivery science and technology2013
Tracking and treating activated T cells.
Article in Journal of drug delivery science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Tailoring lipid nanoparticles for T-cell targeting in allergic asthma: Insights into efficacy and specificity.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024Article
- Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- T-cell targeted pulmonary siRNA delivery for the treatment of asthma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Removal of Fc Glycans from [Molecular pharmaceutics · 2020Article
- Coming in and Finding Out: Blending Receptor-Targeted Delivery and Efficient Endosomal Escape in a Novel Bio-Responsive siRNA Delivery System for Gene Knockdown in Pulmonary T Cells.Advanced therapeutics · 2019Article
- Evaluating the Regulation of Cytokine Levels After siRNA Treatment in Antigen-Specific Target Cell Populations via Intracellular Staining.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.Molecules (Basel, Switzerland) · 2016Review
- Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma.Archiv der Pharmazie · 2015Review
- siRNA delivery to the lung: what's new?Advanced drug delivery reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Upon activation, T cells of various subsets are the most important mediators in cell-mediated immune responses. Activated T cells play an important role in immune system related diseases such as chronic inflammatory diseases, viral infections, autoimmune disease, transplant rejection, Crohn disease, diabetes, and many more. Therefore, efforts have been made to both visualize and treat activated T cells specifically. This review summarizes imaging approaches and selective therapeutics for activated T cells and gives an outlook on how tracking and treating can be combined into theragnositc agents for activated T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.